Kennedy Capital Management LLC Buys 40,193 Shares of Pfizer Inc. (NYSE:PFE)

Kennedy Capital Management LLC lifted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 24.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 206,886 shares of the biopharmaceutical company's stock after buying an additional 40,193 shares during the period. Kennedy Capital Management LLC's holdings in Pfizer were worth $5,489,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of PFE. Nordea Investment Management AB increased its holdings in shares of Pfizer by 36.1% during the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after buying an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI boosted its position in Pfizer by 118.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after acquiring an additional 159,984 shares during the last quarter. Copley Financial Group Inc. acquired a new position in Pfizer in the third quarter valued at approximately $577,000. Mcdonald Partners LLC raised its holdings in shares of Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock valued at $2,926,000 after purchasing an additional 9,963 shares during the period. Finally, Merit Financial Group LLC grew its stake in Pfizer by 60.8% in the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock valued at $3,395,000 after acquiring an additional 48,397 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Pfizer Trading Up 0.9 %

Shares of PFE traded up $0.19 during trading hours on Monday, reaching $22.10. 61,888,490 shares of the company traded hands, compared to its average volume of 40,318,768. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company's fifty day moving average price is $25.25 and its two-hundred day moving average price is $26.38. The company has a market capitalization of $125.34 billion, a price-to-earnings ratio of 15.67, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on PFE shares. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $31.07.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.